Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and
efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Theorion Pharmaceutical Co Ltd.
Collaborator:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences